Welcome to our dedicated page for Fresh Tracks Therapeutics news (Ticker: FRTX), a resource for investors and traders seeking the latest updates and insights on Fresh Tracks Therapeutics stock.
Fresh Tracks Therapeutics, Inc. (FRTX) has undergone a significant transition from a clinical-stage pharmaceutical company focused on skin diseases to an entity in formal dissolution. The news flow around FRTX documents this shift in detail, from its delisting from The Nasdaq Capital Market to its move to the OTC Pink market and, ultimately, to the termination of trading in connection with its dissolution.
Earlier company descriptions characterized Fresh Tracks, previously referred to as Brickell Biotech, Inc., as a developer of innovative and differentiated therapeutics for dermatology indications. More recent press releases, however, center on corporate actions rather than drug development, including special meetings of stockholders to consider a plan of liquidation and dissolution, adjournments of those meetings, and the company’s intention to seek judicial dissolution if stockholder approval could not be obtained.
News items in 2024 and 2025 focus on legal and procedural milestones: a petition in the Delaware Court of Chancery seeking appointment of a custodian to dissolve the company and wind up its affairs; the court’s scheduling orders; and the eventual consent judgment appointing a custodian under Delaware law. Subsequent announcements describe the planned filing of a Certificate of Dissolution, the authorization of an initial cash distribution to stockholders and certain warrant holders, and the expected cessation of trading on the OTC Pink Market.
This FRTX news page serves as an archive of these developments, allowing investors and researchers to follow the sequence of events that led from Nasdaq suspension and OTC Pink quotation to formal dissolution, cash distributions, and the long-term wind-down process overseen by a court‑appointed custodian.
Fresh Tracks Therapeutics (Nasdaq: FRTX) announced significant findings from preclinical studies of FRTX-02, an oral DYRK1A inhibitor, published in the Journal of Translational Autoimmunity. The study highlights FRTX-02's ability to modulate immune responses in models of psoriasis and atopic dermatitis, paving the way for its Phase 1 clinical trial. Topline results from this trial, assessing safety and dosing, are expected by Q1 2023. These preclinical results suggest FRTX-02 may offer a breakthrough approach to treating autoimmune diseases by restoring immune homeostasis.
Fresh Tracks Therapeutics reported progress in its Phase 1 study of FRTX-02, completing the single ascending dose (SAD) portion and initiating the multiple ascending dose (MAD) segment. Topline results are expected by early 2023. The company has $11.3 million in cash and revenue of $0.5 million for Q3 2022, a significant increase from $0.1 million the previous year. R&D expenses decreased to $3.6 million, while G&A expenses slightly fell to $3.0 million. The net loss narrowed to $6.0 million compared to $13.3 million in Q3 2021. Fresh Tracks continues to develop its pipeline, including FRTX-10.
Fresh Tracks Therapeutics (Nasdaq: FRTX) will release its third quarter financial results on November 10, 2022, at 4:30 PM EST. The company, focused on developing innovative therapeutics for autoimmune and inflammatory diseases, aims to disrupt traditional treatment paradigms. Following the earnings report, management will host a conference call to discuss results and corporate highlights. Investors can access the call via phone or a live audio webcast on the company’s website. A replay of the call will be available for 90 days post-event.
Fresh Tracks Therapeutics (FRTX) has initiated the multiple ascending dose (MAD) portion of its Phase 1 clinical trial for FRTX-02, a new DYRK1A inhibitor aimed at treating autoimmune and inflammatory diseases. The trial, which is ongoing in Canada, follows a successful single ascending dose (SAD) phase, demonstrating good safety and tolerability. Topline results are expected by early 2023. FRTX-02 shows potential to restore immune balance, setting the stage for a new treatment paradigm in autoimmune diseases.